The invention provides a pharmaceutical composition for treating rhinitis, which is a preparation prepared from the following raw medicines in parts by weight: 12-18 parts of
agastache rugosus, 15-25 parts of radix scrophulariae, 6-12 parts of magnolia flower, 7-13 parts of radix rubiae, 9-15 parts of thunberg fritillary
bulb, 6-12 parts of
radix bupleuri, 7-13 parts of
angelica sinensis, 12-18 parts of
uncaria rhynchophylla, 12-18 parts of mint, 12-18 parts of loofah
sponge, 12-18 parts of
honeysuckle stem, 5-11 parts of liquorice, 7-13 parts of radix angelicae, 7-13 parts of
lumbricus, 7-13 parts of pericarpium granati, 7-13 parts of fructus chebulae, 4-8 parts of
periostracum cicada, 7-13 parts of
astragalus membranaceus, 7-13 parts of black tenuifolia, 7-13 parts of dark plum, 7-13 parts of
cynanchum paniculatum, 2-5 parts of
cassia twig, 9-15 parts of radix paeoniae alba, 4-8 parts of nidus vespae, 7-13 parts of radix arnebiae seu lithospermi, 7-13 parts of wild
chrysanthemum flower, 15-25 parts of concha ostreae, 9-15 parts of
schisandra chinensis, 12-18 parts of lesser duckweed, 7-13 parts of
eclipta alba, 15-25 parts of
momordica grosvenori and 7-13 parts of platycodon grandiflorum. The pharmaceutical composition disclosed by the invention can be used for effectively treating chronic allergic rhinitis, has the effects of eliminating or relieving symptoms such as rhinobyon, rhinocnesmus, much
nasal mucus, clear
nasal mucus,
olfaction decline, headache or dizziness and the like caused by the rhinitis, also has a high total effective rate in treatment and provides a new choice for clinical medication.